The FIRIS study previously demonstrated non-inferiority of IRIS ( irinotecan plus S-@ ) to FOLFIRI ( @-fluorouracil/leucovorin with irinotecan ) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer ( mCRC ) as the primary endpoint .